Lenalidomide (Revlimid)

General information

Class/mechanism: Second-generation immunomodulatory drug (IMiD) similar to Thalidomide (Thalomid); mechanism not fully understood. Lenalidomide's mechanism may involve immunomodulatory, antiinflammatory, and antiangiogenic effects and suppression of tumor necrosis factor-alpha (TNF-α) from peripheral blood mononuclear cells. It has been observed to inhibit cells with the 5q deletion in myelodysplastic syndromes. It has also been seen in vitro to inhibit cyclooxygenase-2 (COX-2) expression, but not COX-1.
Route: PO
Extravasation: n/a

• Use of Lenalidomide (Revlimid) requires participation the Revlimid REMS program.

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.

Diseases for which it is used

• Adult T-cell leukemia/lymphoma
• Chronic lymphocytic leukemia
• Chronic myelomonocytic leukemia
• Cutaneous T-cell lymphoma
• Diffuse large B-cell lymphoma
• Follicular lymphoma
• Hodgkin lymphoma
• Light-chain (AL) amyloidosis
• Mantle cell lymphoma
• Marginal zone lymphoma
• Multiple myeloma
• Myelodysplastic syndrome
• Myelofibrosis
• Peripheral T-cell lymphoma
• Plasma cell leukemia
• POEMS syndrome
• Polycythemia vera
• Transformed lymphoma
• Waldenström macroglobulinemia

Significant side effects

Thrombosis

• 2006 (two simultaneously published NEJM letters to the editor): link to original article PubMed link to letter #1 PubMed link to letter #2
• 2011: Larocca A, Cavallo F, Bringhen S, Di Raimondo F, Falanga A, Evangelista A, Cavalli M, Stanevsky A, Corradini P, Pezzatti S, Patriarca F, Cavo M, Peccatori J, Catalano L, Carella AM, Cafro AM, Siniscalchi A, Crippa C, Petrucci MT, Yehuda DB, Beggiato E, Di Toritto TC, Boccadoro M, Nagler A, Palumbo A. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood. 2012 Jan 26;119(4):933-9. Epub 2011 Aug 11. link to original article PubMed

Patient drug information

• Lenalidomide (Revlimid) package insert
• Lenalidomide (Revlimid) patient medication guide
• Lenalidomide (Revlimid) patient drug information (Chemocare)
• Lenalidomide (Revlimid) patient drug information (UpToDate)

History of changes in FDA indication

Follicular lymphoma; Marginal zone lymphoma

• 5/28/2019: Approved in combination with a rituximab product for previously treated follicular lymphoma (FL) and previously treated marginal zone lymphoma (MZL). (New disease entity)

Mantle cell lymphoma

• 6/5/2013: Approved for patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib. (New disease entity)

Myelodysplastic syndrome

• 12/28/2005: Approved for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities. (Initial approval)

Multiple myeloma

• 6/29/2006: Approved for treatment of patients with "multiple myeloma (MM), in combination with dexamethasone, in patients who have received at least one prior therapy.] (New disease entity)
• 2/22/2017: Approval expanded as maintenance therapy for patients with multiple myeloma following autologous stem cell transplant. (Approval expanded to maintenance therapy after upfront treatment)

Also known as

• Code names: CC-5013, IMiD-1, NSC-703813
• Brand names: Kabillon, Lenalid, Lenangio, Lenmid, Lenome, Lenzest, MyeloSar, Revlimid